Nxera Pharma Co., Ltd. · TSE:4565
Nxera Pharma — Sosei Group — 40th Annual J.P. Morgan Healthcare Conference (January 2022)
25 slides from Nxera Pharma's conference presentation, Jan 10, 2022
Slide 1: World-leading drug discovery targeting GPCRs
NON – CONFIDENTIAL World-leading drug discovery targeting GPCRs 40th Annual J.P. Morgan Healthcare Conference January 2022 | © Sosei Group Corporation
Slide 2: Disclaimer
Disclaimer The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the “Company”) as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed
Slide 3: We are a world-leading team of GPCR drug hunters
We are a world-leading team of GPCR drug hunters World leader in EVOLVING WITH A SPECIALIST GPCR drug discovery THERAPEUTIC FOCUS and early development Advancing a broad and deep Proprietary GPCR-targeted pipeline of over 40 partnered StaR® technology and SBDD and in-house programs across platform c
Slide 4: We unlock the potential of GPCRs with our StaR technology
We unlock the potential of GPCRs with our StaR® technology GPCRs are well-known targets with StaR® enables us to unlock the potential of GPCRs via advanced significant untapped opportunity understanding of their structure and atomic/molecular interactions Unstable ~400 native GPCR GPCR PROTEINS Stab
Slide 5: Core capabilities in drug discovery and early development
Core capabilities in drug discovery and early development DRUG DISCOVERY/EARLY DEVELOPMENT DRIVEN BY STAR® / SBDD ENGINE LATE STAGE DEVELOPMENT PRE-DISCOVERY DISCOVERY PRECLINICAL PH 1a PH 1b PH 2/3 APPROVAL StaR® Technology SBDD DMPK SAD Dosing assessment • Strategic tactical development Structure
Slide 6: Our approach is validated through 20+ active GPCR programs with world class partners
Our approach is validated through 20+ active GPCR programs with world class partners Active Partnerships Active Spin-Out Asset Centric Vehicles Upfront and milestone payments, ~$800 royalties and R&D funding ~$7 Total potential deal value of received from partners to date1 active partnerships2 milli
Slide 7: Ten drug candidates generated from our SBDD platform have advanced into clinical trials
Ten drug candidates generated from our SBDD platform have been successfully advanced into clinical trials in the past 7 years TODAY* Generated 25 LEAD OP preclinical 6 programs Acquisition of Heptares candidates by Sosei PRECLINICAL Produced 9 candidates 10 CLINICAL clinical candidates 9 candidates
Slide 8: Broad and balanced pipeline of partnered and in-house programs
Broad and balanced pipeline of partnered and in-house programs, plus new technology collaborations will drive long-term momentum Pre-Disc. / Discovery Preclinical studies Phase 1 Phase 2 Marketed Multi-target M1M4 ag. M4 ag. HTL’878 GLP-1 ag. A2a ant. combo(s)** Ultibro® Breezhaler® Multiple Neurolo
Slide 9: New strategic collaboration with Neurocrine to progress selective Muscarinic agonists
New strategic collaboration with Neurocrine to progress a portfolio of selective Muscarinic agonists $100m upfront received and up to $2.6bn in future economics Neurocrine gained rights to a portfolio of potential best-in-class selective Licensed Portfolio 1 muscarinic receptor agonists in developme
Slide 10: Neurocrine M4 agonist (HTL'878) program – 4th-gen candidate for schizophrenia
Neurocrine M4 agonist (HTL’878) program – 4th-gen candidate aiming to be a highly effective and safer treatment for Sz Efficacy Safety Positive Negative Cognitive Extrapyramidal Weight gain symptoms symptom impairment symptoms** Peak sales Number of patients Number of patients Number of patients MoA
Slide 11: Four upcoming wholly-owned programs prioritised for development
Four upcoming wholly-owned programs prioritised for development over the next 12 to 24 months Schizophrenia Atopic Immunosuppression Inflammatory and Psychosis Dermatitis in solid tumors Bowel Disease GPR52 agonist H4 antagonist EP4 antagonist EP4 agonist TARGET PRODUCT PROFILE • Once daily oral • O
Slide 12: New initiatives and future innovations
New initiatives and future innovations 12
Slide 13: Strategic growth plan driving corporate value expansion
Strategic growth plan driving corporate value expansion OBJECTIVE OBJECTIVE STRATEGIC GROWTH PLAN Add new technology Capital raise capabilities to our completed to pursue SBDD platform revenue focused deals in 2022 P P Seek out revenue- Invest / collaborate in generating opportunities novel technolo
Slide 14: Three big challenges in drug discovery and development
Three big challenges in drug discovery and development KEY OPPORTUNITY Choosing Discovering Conducting the right target a therapeutic agent the right patient studies • Will modulating the target • Identifying a modulator with • Demonstrating the value of affect disease? the appropriate profile the a
Slide 15: AI / Machine Learning
In January 2021 we established our New target ID and validation (TIV) framework to accelerate our hunt for novel GPCR targets… To support the identification and validation of new drug GPCR targets Bioinformatics AI / Machine Learning Aim across our core therapeutic areas (GI, Proteomics immunology,
Slide 16: ...with three new key partnerships executed in the past 12 months
...with three new key partnerships executed in the past 12 months • Research collaboration combining • Discovery collaboration • Discovery collaboration Verily’s immune profiling combining InveniAI’s AI-powered combining Twist’s synthetic capabilities and SH’s StaR® platform for target discovery wit
Slide 17: New multi-target collaboration with Verily
New multi-target collaboration with Verily aims to accelerate the development of novel therapies for immune-mediated diseases 300+ Potential High priority Structure-based GPCRs candidate targets drug development Immune Profiler StaR® Platform Data Analysis 8 million readouts per sample Integrative a
Slide 18: We are building a Future Innovations Portfolio
We are building a Future Innovations Portfolio to explore ways to leverage our platform expertise in new directions Targeted GPCR Degradation Ion Channels COVID-19 Treatment • Technology collaboration to • Technology collaboration to • In-house program funded by initially identify novel small demons
Slide 19: Priority objectives for FY2022
Priority objectives for FY2022 Progress organic Execute strategic Commitment to sustainable growth plan growth plan development goals • Extend technology / platform • Invest / collaborate in novel • Promote sustainable ESG leadership technologies practices and policies across • Generate high quality
Slide 20: Appendix
Appendix 20
Slide 21: Our new partner Neurocrine is committed to a transformative treatment for Schizophrenia
Our new partner Neurocrine is committed to a transformative treatment for Schizophrenia with the M4 agonist HTL-0016878 Large addressable market with …Limited innovation Huge opportunity for M4 blockbuster sales profiles… in 70 years agonists including HTL-0016878 Schizophrenia patients Current trea
Slide 22: Partnered Pipeline
Partnered Pipeline Compound Target / Mechanism of Action Modality Indication Partner Disc. PCC Ph1 Ph2 Ph3 App Mkt Traditional Out-licensing Collaborations Seebri® Breezhaler® LAMA SME COPD Ultibro® Breezhaler® LAMA+LABA SME COPD Enerzair® Breezhaler® LAMA+LABA+ICS SME Asthma ORAVI® Antifungal agent
Slide 23: Partnered Pipeline (cont'd)
Partnered Pipeline (cont’d) Compound Target / Mechanism of Action Modality Indication Partner Disc. PCC Ph1 Ph2 Ph3 App Mkt Co-development / Profit-share Collaborations KY1051 CXCR4 mAb mAb Immuno-oncology Not disclosed PAR-2 Peptide Inflammatory diseases Not disclosed Targeted Protein Degradation S
Slide 24: In-house Pipeline
In-house Pipeline Compound Target / Mechanism of Action Modality Indication Originator Dis PCC Ph1 Ph2 Ph3 App Mkt. In-house Programs (Not yet partnered) Not disclosed H4 antagonist SME Atopic Dermatitis Not disclosed EP4 antagonist SME Immuno-oncology Not disclosed GPR52 agonist SME Neurology disea
Slide 25: IR@soseiheptares.com
IR@soseiheptares.com SOSEI HEPTARES PMO Hanzomon 11F Steinmetz Building North West House 2-1 Kojimachi, Chiyoda-ku Granta Park, Cambridge 119 Marylebone Road Tokyo 102-0083 CB21 6DG London NW1 5PU Japan United Kingdom United Kingdom www.soseiheptares.com @soseiheptaresco @soseiheptaresco @soseihepta
Sosei Group — 40th Annual J.P. Morgan Healthcare Conference (January 2022) on 6ix